Infective Endocarditis Complicated with Progressive Heart Failure due to β-Lactamase-Producing
            <i>Cardiobacterium hominis</i>

Lu, Po‐Liang; Hsueh, Po‐Ren; Hung, Chien‐Ching; Teng, Lee-Jene; Jang, Tsrang-Neng; Luh, Kwen‐Tay

doi:10.1128/jcm.38.5.2015-2017.2000

Cited by 38 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over a quarter of patients finished treatment with β-lactam monotherapy. However, because of reports of beta-lactamaseproducing C. hominis strains causing endocarditis [24,26], it seems prudent to use a thirdgeneration cephalosporin as first-line treatment, in accordance with recently published American Heart Association guidelines [67].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cardiobacterium hominis endocarditis: two cases and a review of the literature

Malani

Aronoff

Bradley

et al. 2006

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Cardiobacterium hominis, a member of the HACEK group (Haemophilus parainfluenzae, Haemophilus aphrophilus, and Haemophilus paraphrophilus, Actinobacillus actinomycetemcomitans, C. hominis, Eikenella corrodens, and Kingella species), is a rare cause of endocarditis. There are 61 reported cases of C. hominis infective endocarditis in the English-language literature, 15 of which involved prosthetic valve endocarditis. There is one reported case of C. hominis after upper endoscopy and none reported after colonoscopy. Presented here are two cases of C. hominis prosthetic valve endocarditis following colonoscopy and a review of the microbiological and clinical features of C. hominis endocarditis. Patients with C. hominis infection have a long duration of symptoms preceding diagnosis (138+/-128 days). The most common symptoms were fever (74%), fatigue/malaise (53%), weight loss/anorexia (40%), night sweats (24%), and arthralgia/myalgia (21%). The most common risk factors were pre-existing cardiac disease (61%), the presence of a prosthetic valve (28%), and history of rheumatic fever (20%). Of the 61 cases reviewed here, the aortic valve was infected in 24 (39%) and the mitral valve in 19 (31%) patients. The average duration of blood culture incubation before growth was detected was 6.3 days (range, 2-21 days). Complications were congestive heart failure (40%), central nervous system (CNS) emboli (21%), arrhythmia (16%), and mycotic aneurysm (9%). C. hominis is almost always susceptible to beta-lactam antibiotics. Ceftriaxone is recommended by the recently published American Heart Association guidelines. The prognosis of C. hominis native valve and prosthetic valve endocarditis is favorable. The cure rate among 60 patients reviewed was 93% (56/60). For prosthetic valve endocarditis, the cure rate was 16/17 (94%). Valve replacement was required in 27 (45%) cases.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Almost all isolates have been susceptible to penicillins, cephalosporins, tetracyclines, chloram-phenicol, and aminoglycosides. Recently, two isolates with beta-lactamase production have been reported [24,26]. Susceptibility testing was performed on the isolates from both of our patients.…”

Section: Treatment and Susceptibilitymentioning

confidence: 99%

Cardiobacterium hominis endocarditis: two cases and a review of the literature

Malani

Aronoff

Bradley

et al. 2006

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

“…The overall prognosis of endocarditis due to C. hominis is quite favorable, despite the frequent need for valve replacement. Penicillin along with an aminoglycoside used to be the therapy of choice and was the most frequently used regimen in the above mentioned review [8]. There have been recent reports of β-lactamase-producing isolates, with high minimal inhibitory concentration to penicillin and ampicillin [8].…”

Section: Journal Of Clinical Case Reportsmentioning

confidence: 99%

“…Penicillin along with an aminoglycoside used to be the therapy of choice and was the most frequently used regimen in the above mentioned review [8]. There have been recent reports of β-lactamase-producing isolates, with high minimal inhibitory concentration to penicillin and ampicillin [8]. As a result, the American Heart Association (AHA) now recommends ceftriaxone (2 g i.v.…”

Section: Journal Of Clinical Case Reportsmentioning

confidence: 99%

Cardiobacterium Hominis Endocarditis of Bioprosthetic Pulmonic Valve: Case Report and Review of Literature

Fazili

Endy²,

Javaid³

et al. 2013

J Clin Case Rep

View full text Add to dashboard Cite

“…Eighty-three per cent (24 of 29) of cases in the literature have described at least one of these symptoms . Orthopnea and dyspnea may be a part of the presentation if the valvular lesion has progressed to the point where it is causing heart failure (3,38,43). This was the case with the patient described in the present report.…”

Section: Andrew Walkty MDmentioning

confidence: 99%

Cardiobacterium hominis Endocarditis: A Case Report and Review of the Literature

Walkty

2005

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

The present case report describes the clinical course of a patient who presented with Cardiobacterium hominis endocarditis. A review of the literature follows the case presentation. C hominis, a fastidious Gram-negative bacillus, is a member of the HACEK group of microorganisms (Haemophilus species, Actinobacillus actinomycetemcomitans, C hominis, Eikenella corrodens and Kingella kingae). Endocarditis caused by C hominis is uncommon and generally follows a subacute course. Patients may present with constitutional symptoms, symptoms related to valvular destruction or symptoms secondary to embolic events. Diagnosis requires identification of the pathogen from blood or vegetation by either culture or molecular techniques. Blood cultures may require prolonged incubation, highlighting the importance of incubating blood cultures for at least two to three weeks in patients with suspected endocarditis. In the past, C hominis was generally sensitive to penicillin. However, reports of beta-lactamase-producing C hominis have appeared in the literature over the past decade. The current recommendation for first-line treatment is a third-generation cephalosporin (ceftriaxone) for four weeks (six weeks if a prosthetic valve is in place).

show abstract

Infective Endocarditis Complicated with Progressive Heart Failure due to β-Lactamase-Producing Cardiobacterium hominis

Cited by 38 publications

References 15 publications

Cardiobacterium hominis endocarditis: two cases and a review of the literature

Cardiobacterium hominis endocarditis: two cases and a review of the literature

Cardiobacterium Hominis Endocarditis of Bioprosthetic Pulmonic Valve: Case Report and Review of Literature

Cardiobacterium hominis Endocarditis: A Case Report and Review of the Literature

Contact Info

Product

Resources

About